CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study compares three different drug combinations for people with head and neck cancer that has spread or returned after immunotherapy stopped working. About 430 adults will receive either standard chemo plus cetuximab, chemo plus bevacizumab, or a combination of atezolizumab…
Matched conditions: CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:25 UTC
-
Promising combo aims to shrink tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (cemiplimab) to low-dose chemotherapy can shrink tumors in people with head and neck cancer that has returned or spread. About 46 adults who have not had prior treatment for advanced disease will receive the combination. The m…
Matched conditions: CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 17, 2026 03:24 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive the immunotherapy drug pembrolizumab plus chemotherapy. Half also get targeted radiation to their tumors. The goal is to see if adding radiation helps …
Matched conditions: CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Head and neck cancer trial tests easier chemo schedule
Disease control TerminatedThis study compares two different schedules of the chemotherapy drug cisplatin given alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose every week. The goal is to see which schedule causes f…
Matched conditions: CLINICAL STAGE IV HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 11, 2026 20:47 UTC